Detection of epidermal growth factor receptor (EGFR) mutations for lung adenocarcinoma is crucial since tyrosine kinase inhibitors (TKI) are tailored for treatments in lung adenocarcinoma with EGFR mutations (1–3). Here, EGFR is linked to lung adenocarcinoma.